# Efficacy of STABLOR® on Visceral Fat Mass Reduction in Patients With Metabolic Syndrome

> **NCT03692806** · NA · COMPLETED · sponsor: **LNC THERAPEUTICS** · enrollment: 240 (actual)

## Conditions studied

- Metabolic Syndrome

## Interventions

- **DIETARY_SUPPLEMENT:** Stablor
- **DIETARY_SUPPLEMENT:** placebo

## Key facts

- **NCT ID:** NCT03692806
- **Lead sponsor:** LNC THERAPEUTICS
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-09-11
- **Primary completion:** 2019-10-31
- **Final completion:** 2020-12-16
- **Target enrollment:** 240 (ACTUAL)
- **Last updated:** 2020-12-17

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03692806

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03692806, "Efficacy of STABLOR® on Visceral Fat Mass Reduction in Patients With Metabolic Syndrome". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03692806. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*